France· FR:60690011
KESIMPTA 20 mg, solution injectable en stylo prérempli
A medicinal product containing ofatumumab, registered in France by NOVARTIS EUROPHARM (IRLANDE), on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- OFATUMUMAB
- Manufacturer
- NOVARTIS EUROPHARM (IRLANDE)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip1334009302269711 stylo prérempli en verre de 0,4 mlEUR 1.16
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ofatumumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- IrelandKesimpta 20 mg solution for injection in pre-filled penNovartis Europharm Limited
- NetherlandsKesimpta 20 mg, oplossing voor injectie in voorgevulde penNovartis Europharm Limited
- BelgiumArzerra 100 mgNovartis Europharm
- FinlandArzerraNovartis Europharm Limited
- CzechiaKESIMPTANovartis Europharm Limited, Dublin
- United KingdomArzerra 1000mg/50ml concentrate for solution for infusion vialsNovartis Pharmaceuticals UK Ltd
- SpainKESIMPTA 20 mg SOLUCION INYECTABLE EN PLUMA PRECARGADANovartis Europharm Limited
- IcelandKesimptaNovartis Europharm Limited*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Kesimpta
- Liechtenstein · Kesimpta
- Norway · Kesimpta
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/85782217-8497-4264-9ac1-5db296219145 GET /v1/drugs/85782217-8497-4264-9ac1-5db296219145?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "60690011",
"date_amm": "2021-03-26",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/21/1532",
"substance": "OFATUMUMAB",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution injectable",
"voies_administration": "sous-cutanée",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about ofatumumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.